Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32804
- Translational Research Institute for Metabolism and Diabetes
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to communicate meaningfully with the investigator and legally competent to provide informed written consent
- Age 18 - 45 years, inclusive
- Weight stable (+/- 3 kg) during the 6 months prior to enrollment
- BMI ≤ 30 kg/m2
Exclusion Criteria:
- History or presence of cardiovascular disease (unstable angina, myocardial infarction or coronary revascularization within 6 months, clinically significant abnormalities on EKG, presence of cardiac pacemaker, implanted cardiac defibrillator)
- History of type 1 or type 2 diabetes
- Bleeding disorders
- Acute or chronic infections
- Hepatitis and/or cirrhosis
- Severe asthma or chronic obstructive pulmonary disease
- Renal insufficiency or nephritis
- Thyroid dysfunction (suppressed TSH, elevated TSH if symptomatic, elevated thyroid stimulating hormone (TSH) if asymptomatic)
- Uncontrolled hypertension (BP >160 mmHg systolic or >100 mmHg diastolic)
- Prior bariatric surgery
- Inflammatory bowel disease or malabsorption, swallowing disorders, suspected or known strictures, fistulas or physiological/mechanical GI obstruction, history of gastrointestinal surgery, Crohn's disease or diverticulitis
- Participants with strict dietary concerns (e.g. vegetarian or kosher diet, multiple food allergies, or allergies to food we will provide them during the study)
- Current use of polyethylene glycol (e.g. Dulcolax, Miralax, Gavilax)
- Cancer within the last 3 years (except non-melanoma skin cancer or treated cervical carcinoma in situ)
- History of depression within < 5 years from screening visit or which, in the opinion of a medical investigator, will impact the participant's ability to complete the study
- History of eating disorders
- Cushing's disease or syndrome
- Untreated or inadequately controlled hypo- or hyperthyroidism
- Active rheumatoid arthritis or other inflammatory rheumatic disorder
- Pregnant or nursing females or females less than 6 months postpartum from the scheduled date of collection.
- Tobacco use within the past 3 months
- Metal implants (pace-maker, aneurysm clips) based on Investigator's judgment at Screening.
- Unable to participate in MRI or MRS assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on Investigator's judgment at Screening.
- Unable to tolerate MRI/MRS imaging or claustrophobia.
- Nickel allergy.
- Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pretrial (screening) visit.
- Intolerance to acetaminophen use.
- History of regular alcohol consumption exceeding 7 drinks/week for female participants or 14 drinks/week for male participants (1 drink = 5 ounces [150 mL] of wine or12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months before screening.
- Anemia (hemoglobin <12 g/dl in men, <11 g/dl in women)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control Western diet
Participants will consume a control western diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period.
|
Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
|
|
Experimental: Microbiome Enhancer diet
Participants will consume an experimental microbiome enhancer diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period
|
Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The primary endpoint for the protocol is the within-participant difference in fecal energy (via chemical oxygen demand, COD) normalized to the total daily energy intake and to the non-metabolizable marker PEG [COD (kcal) / PEG (g)].
Time Frame: Days 24-29 vs. Days 53-58
|
Comparison within subject of control diet versus microbiome enhancer diet.
|
Days 24-29 vs. Days 53-58
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Rosa Krajmalnik-Brown, PhD, Study Principal Investigator at Arizona State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- TRIMD FH 942699
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.